PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.
PRO-051 (GSK-2402968), being developed by GlaxoSmithKline plc, under license from Leiden University Medical Center and Prosensa Therapeutics BV, is a 2'-O-methyl phosphorothioate antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy (DMD). The PRO-051 oligonucleot...
| Auteurs principaux: | , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
2010
|